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Abstract: Vitamin D and cholesterol metabolism overlap significantly in the pathways that contribute
to their biosynthesis. However, our understanding of their independent and co-regulation is limited.
Cardiovascular disease is the leading cause of death globally and atherosclerosis, the pathology
associated with elevated cholesterol, is the leading cause of cardiovascular disease. It is therefore
important to understand vitamin D metabolism as a contributory factor. From the literature, we
compile evidence of how these systems interact, relating the understanding of the molecular mecha-
nisms involved to the results from observational studies. We also present the first systems biology
pathway map of the joint cholesterol and vitamin D metabolisms made available using the Systems
Biology Graphical Notation (SBGN) Markup Language (SBGNML). It is shown that the relationship
between vitamin D supplementation, total cholesterol, and LDL-C status, and between latitude,
vitamin D, and cholesterol status are consistent with our knowledge of molecular mechanisms. We
also highlight the results that cannot be explained with our current knowledge of molecular mecha-
nisms: (i) vitamin D supplementation mitigates the side-effects of statin therapy; (ii) statin therapy
does not impact upon vitamin D status; and critically (iii) vitamin D supplementation does not
improve cardiovascular outcomes, despite improving cardiovascular risk factors. For (iii), we present
a hypothesis, based on observations in the literature, that describes how vitamin D regulates the
balance between cellular and plasma cholesterol. Answering these questions will create significant
opportunities for advancement in our understanding of cardiovascular health.
Keywords: cholesterol; vitamin D; systems biology; regulation; pathway biology
1. Introduction
Interest in vitamin D has expanded significantly in recent years with the number of
publications featuring the fat-soluble vitamin growing rapidly. Vitamin D has a crucial role
in skeletal health, affecting bone mineralisation and calcium and phosphate homeostasis
along with the regulation of the parathyroid hormone [1,2]. Traditionally, vitamin D
deficiency is associated with the pathogenesis of rickets and osteomalacia, affecting children
and adults, respectively [3,4]. However, more recently, the dysregulation of vitamin D has
been implicated in a range of immunological conditions including cancer [5], respiratory
conditions [6], rheumatoid arthritis [7], and diabetes [8], underscoring its important role as
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an immunomodulator [9]. Hence, recent studies have investigated the efficacy of vitamin
D supplementation as a treatment strategy across a multitude of conditions [10,11].
Intriguingly, vitamin D is inextricably linked with cholesterol metabolism with the
two metabolisms sharing an extensive common biosynthesis pathway. Cholesterol is a
lipid with many roles. It is a vital component of cellular membranes [12], a precursor to
bile acids, steroids, and oxysterols [13], and is implicated in neurological development [14],
cardiovascular health [15,16], innate immunity [17,18], and gallbladder disease [19]. Impor-
tantly, its dysregulation can result in elevated total blood cholesterol, and LDL-C, which
have been associated with cardiovascular risk [16,20]. The interplay between the two
metabolic pathways is complex. For instance, vitamin D deficiency has been associated
with increased incidence of CVD [21,22] and vitamin D supplementation has been related
to an improvement in atherogenic lipid markers [23]. However, many studies have re-
ported that cardiovascular events were ultimately unaffected by supplementation [24–26].
Even more intriguingly, evidence suggests that statin therapy, used in the treatment of
hypercholesterolaemia, does not influence the plasma levels of vitamin D [27]. This is
counter-intuitive, as statins inhibit a key mechanism in the biosynthesis pathway shared by
both metabolisms. Moreover, it has been observed that vitamin D supplementation reduces
the side effects associated with statin treatment [28], reduces the concentration of the statin
and its metabolites, whilst conversely enhancing the action of statins [29]. Additionally, it
is clear that dysregulation of cholesterol and vitamin D metabolism occurs with age and
that dysregulation correlates with a rise in age-associated diseases [30,31], but it is poorly
understood how this dysregulation develops.
The interplay between these two elaborate metabolic pathways can be best described
with the use of systems biology, which enables their complex biochemical interactions to
be viewed in an integrated manner. In this paper, we begin by exploring the known role of
cholesterol in health and disease and then the known role of vitamin D in health and disease.
Next, the bidirectional relationship between cholesterol and vitamin D metabolisms is
outlined before we discuss the role of statins, the feedback mechanisms at play, and the
role of known and mutations. Following this, the role of systems biology is emphasised
by compiling a detailed review of the computational models of the two pathways. Finally,
we describe the development of a new systems biology network diagram that underpins
these complex metabolic pathways. This allows us to explore experimental results and
observations in the context of systems level behaviour and ultimately to identify which
results are consistent with our systems level understanding and which results are in
contradiction.
2. Cholesterol in Health and Disease
Cholesterol is absorbed from the diet and synthesized in cellular pathways with
biosynthesis contributing approximately 80% of serum cholesterol [32]. The liver plays a
central role in synthesizing and regulating cholesterol biosynthesis [33,34]. Blood choles-
terol is determined by multiple factors: biosynthesis, dietary intake, absorption, cellular
uptake, cellular efflux, excretion metabolism to bile acids [35]. It is well established that
elevated blood cholesterol is associated with increased cardiovascular risk. This is due
to the role that cholesterol plays in the pathogenesis of atherosclerosis. In this process,
low density lipoproteins, containing triglycerides and carry cholesterol, form low density
lipoprotein cholesterol (LDL-C) particles that undergo oxidation, and are taken up by
macrophages, which consequently transition to foam cells. This drives plaque formation
and chronic inflammation at sites of endothelial damage. Atherosclerosis is, the leading
cause of cardiovascular disease (CVD) [16,36,37], which itself is the leading cause of death
globally (WHO Global Health Observatory). In patients with elevated blood cholesterol,
interventions aim to lower LDL-C to <1.4 mmol/L (<55 mg/dL). The European Society
for Cardiology guidelines suggest that blood cholesterol should be lowered by 50% with a
baseline of 1.8 mmol/L–3.5 mmol/L [38].
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Cholesterol is synthesized by the mevalonate, Bloch, and Kandutsch–Russell path-
ways [13]. These pathways are downregulated by the statin class of molecules that targets
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the enzyme that cataly-
ses a key interaction toward the start of the mevalonate pathway to reduce the rate of
cholesterol biosynthesis [39]. Statins serve as the primary pharmaceutical intervention
for elevated blood cholesterol [13,40,41] and have been demonstrated to be highly effec-
tive in preventing cardiovascular disease [42,43]. However, statin treatment can induce
adverse effects, the most common being myositis, myopathy, and myalgia [44,45] and,
less frequent, but more severe, rhabdomyolysis [46]. It has been estimated that 10–15% of
patients using statin therapy experience such effects [47]. Statins are also known to have
anti-inflammatory effects, though the mechanism of action is not well understood [48,49].
NLRP3, an intracellular danger-sensing complex, is implicated in how statins effect the
immune system, driving pro-inflammatory responses via the IL-1beta and IL-18 pathways,
both associated with coronary artery disease progression and plaque rupture [50–52].
Where statin treatments are ineffective or induce severe side-effects, alternative treat-
ments include intestinal absorption inhibitors such as ezetimibe that reduce absorption
from diet, but do not regulate cholesterol biosynthesis [53]. Phytosterols similarly block
cholesterol absorption [54] and bile acid sequestrants and niacin can also be used in treat-
ment [55,56]. LDL receptors (LDLr) are responsible for cellular uptake of LDL-C from
the blood and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) targets the LDL
receptors (LDLr) for lysosomal degradation [57]. In recent years, proprotein convertase
subtilisin kexin 9 (PCSK9) inhibitors have been approved as treatments by the U.S. Food
and Drug Administration (FDA) and European Medicines Agency (EMA) [58]. These
treatments inhibit the PCSK9 mediated degradation of LDLr, increasing the abundance of
LDLr and the cellar uptake of LDL-C [57,59]. Moreover, currently being investigated are
cholesterylester transfer protein (CETP) inhibitors that reduce the transfer of high density
lipoprotein cholesterol (HDL-C), which itself is inversely correlated with risk, to athero-
genic LDL-C [60,61], and Bempedoic acid that inhibits cholesterol biosynthesis upstream of
HMGCR [62]. A schematic of how these treatments affect cholesterol metabolism is shown
in Figure 1.
Cells 2021, 10, x FOR PEER REVIEW 3 of 20 
 
 
Cardiology guidelines suggest that blood cholesterol should be lowered by 50% with a 
baseline of 1.8 mmol/L–3.5 mmol/L [38].  
Cholesterol is synthesized by the mevalonate, Bloch, and Kandutsch–Russell 
pathways [13]. These pathways are downregulated by the statin class of molecules that 
targets 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the enzyme that 
catalyses a key interaction toward the start of the mevalonate pathway to reduce the rate 
of cholesterol biosynthesis [39]. Statins serve as the primary pharmaceutical intervention 
for elevated blood cholesterol [13,40,41] and have been demonstrated to be highly 
effective in preventing cardiovascular disease [42,43]. However, statin treatment can 
induce adverse effects, the most common being myositis, myopathy, and myalgia [44,45] 
and, less frequent, but more severe, rhabdomyolysis [46]. It has been estimated that 10–
15% of patients using statin therapy experience such effects [47]. Statins are also known 
to have anti-inflammatory effects, though the mechanism of action is not well understood 
[48,49]. NLRP3, an intracellular danger-sensing complex, is implicated in how statins 
effect the immune system, driving pro-inflammatory responses via the IL-1beta and IL-18 
pathways, both associated with coronary artery disease progression and plaque rupture 
[50–52].  
Where statin treatments are ineffective or induce severe side-effects, alternative 
treatments include intestinal absorption inhibitors such as ezetimibe that reduce 
absorption from diet, but do not regulate cholesterol biosynthesis [53]. Phytosterols 
similarly block cholesterol absorption [54] and bile acid sequestrants and niacin can also 
be used in treatment [55,56]. LDL receptors (LDLr) are responsible for cellular uptake of 
LDL-C from the blood and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) targets 
the LDL receptors (LDLr) for lysosomal degradation [57]. In recent years, proprotein 
convertase subtilisin kexin 9 (PCSK9) inhibitors have been approved as treatments by the 
U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) [58]. 
These treatments inhibit the PCSK9 mediated degradation of LDLr, increasing the 
abundance of LDLr and the cellar uptake of LDL-C [57,59]. Moreover, currently being 
investigate  are cholesterylester transfer protein (CETP) inhibitors that reduce the 
transfer of high de sity lipoprotein cholester l (HDL-C), w ich it elf is inversely 
correlated with risk, to atherogenic LDL-C [60,61], and Bemp doic acid that inhibits 
cholesterol biosynthesis upstream of HMGCR [62]. A chema ic f h w these treatm nts 
affect cholesterol metabolism is shown in Figure 1. 
 
Figure 1. A schematic of the various medications that can be used to lower LDL-C (atherogenic, in 
red) and raise HDL-C (atheroprotective, in blue). 
Mutations in LDLr, endocytic adaptor molecules such as PCSK9 and proteins 
involved in LDL formation such as APOB can cause familial hypercholesterolemia, a 
Figure 1. A schematic of the various medications that can be used to lower LDL-C (atherogenic, in
red) and raise HDL-C (atheroprotective, in blue).
Mutations in LDLr, endocytic adaptor molecules such as PCSK9 and proteins involved
in LDL formation such as APOB c n cause familial hypercholesterolemia, a hereditary
c nditio that elevates serum cholesterol and increases cardiovascular ri k, aff ct ng ap-
proximately one in 300 of the population [15,63,64].
Dysregulation of cholesterol and vitamin D metabolism is often observed with advanc-
ing age and is associated with an elevated risk of age-related diseases [30,31]. However,
our understanding of the development of this dysregulation is ambiguous. Total serum
cholesterol and LDL-C increase with age in both men and women up until the midpoint
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of life [65–69]. HDL-C is influenced considerably less by age [70,71]. In older people
(>65 years), it has been observed that total serum cholesterol and LDL-C concentrations are
lower than those in middle age and it is uncertain why this is the case. However, it has
been speculated that this may be due to survival bias and decreased liver function [66].
At sites of atherosclerotic plaque formation, endothelial cells have been shown to have
reduced telomere lengths and to show markers of cellular ageing, suggesting the presence
of age-related disease [72,73]. There is also evidence for the relationship between lipid
metabolism, longevity and healthspan with an association shown between health ageing,
lipid profiles and genetic variants in enzymes that impact upon lipid metabolism, such as
apolipoprotein E [74].
The age-related dysregulation of cholesterol metabolism is associated with multiple
mechanistic changes that take place during ageing. The efficiency of cholesterol absorption
increases with age, and this could be due to several factors. It is biologically plausible that
there is an age-related increase in NPC1L1 a protein implicated in intestinal cholesterol
absorption [75] and that there is age-related disruption of hepatic lipoprotein processing. It
has been found that both the number and activity of hepatic LDLrs diminish in ageing rats
and that this was associated with retarded chylomicron clearance [76]. In humans, age has
been found to correlate with the residence time of LDL apoB-100 [77]. It is not known why
the integrity of LDLr is compromised during ageing, but activation of the mammalian target
of rapamycin (mTOR) complex may be involved [78]. It is to be expected that dysregulation
of LDLr during ageing will elevate hepatic cholesterol levels and that this will result
in a rise in plasma cholesterol levels. Other ageing processes impinging on cholesterol
metabolism include oxidative damage via reactive oxygen species (ROS), which has been
widely hypothesised to have a key role in ageing and age-related pathology [79]. Several
lines of evidence substantiate the view that ROS are involved in cholesterol metabolism.
Tentative empirical evidence from rodent studies suggest that an age-related increase
in hepatic levels of ROS can provoke a rise in cholesterol biosynthesis, although recent
computational work was unable to confirm this [67].
3. Vitamin D in Health and Disease
The active form of vitamin D (calcitriol, 1,25(OH)2D) is synthesised in a sequence
of metabolic steps that span extracellular regions, the cytosol, lysosome, endoplasmic
reticulum and mitochondria [2,80]. The metabolic pathway comprises the mevalonate
pathway and the Kandutsch–Russell branch of the sterol pathways. However, in parallel
with the final step of cholesterol synthesis in the Kandutsch–Russell pathway, UV-radiation
regulates the transition of 7-dehydrocholesterol to pre-vitamin D3, which then isomerises
to form cholecalciferol. Cholecalciferol transforms to calcidiol (25(OH)D), which subse-
quently transforms to the active form calcitriol (1,25(OH)2D) [2,81]. Calcitriol circulates
after binding to vitamin D binding protein (GC) and dissociates in tissues to bind to vitamin
D receptor (VDR) [82], its nuclear receptor transcription factor, from where it maintains cal-
cium and phosphorous homeostatis [83]. However, it also has roles in energy metabolism,
cell proliferation, differentiation, and apoptosis, and vitamin D-binding proteins in other
cellular compartments have been suggested [84].
Vitamin D has been found to affect inflammation and immunity, regulating the pro-
duction of inflammatory cytokines and inhibiting the proliferation of proinflammatory
cells [85]. In particular, vitamin D receptor (VDR) signalling has been shown to inhibit the
NLRP3 mediated immune response, which has been implicated in the anti-inflammatory
effects of statins [86].
The definitions and thresholds for vitamin D deficiency lack a universal consensus [87].
Calcidiol (25(OH)D) is taken as a proxy biomarker of vitamin D status [88]. Deficiency has
variously been defined as serum calcidiol below 25 nmol/L [89], below 30 nmol/L [82] or
below 50 nmol/L [90]. Sufficiency of calcidiol (25(OH)D) has been defined at 50 nmol/L [91]
and optimal calcidiol (25(OH)D) at 80 nmol/L [91,92]. In response, the National Institutes
of Health established the vitamin D standardisation program (VDSP) [93,94], defining
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deficiency as below 50 nmol/L [95]. In the UK, the Scientific Advisory Committee on
Nutrition established 25 nmol/l as a national target [96], whilst the European Food Safety
Authority adopted 50 nmol/L [97]. However, it is estimated that 7% and 26% of the
population of the USA show vitamin D deficiency and that 13% and 40% of the population
of Europe show deficiency on average across the year, when it is defined as <30 nmol/L
and <50 nmol/L, respectively [98].
Vitamin D deficiency is more common in aged populations [99,100] with estimates of
50+% of the community dwelling elderly in the U.S. being deficient [100]. Ageing leads
to reduced levels of 7-dehydrocholesterol in the skin [101] and decreased expression of
vitamin D receptors [102,103], along with reduced calcium absorption in the gut [1]. Muscle
function has been shown to be impaired in elderly osteoporosis patients and vitamin D
status has been associated with the risk of falls [104,105].
Vitamin D deficiency is associated with osteomalacia and rickets, amongst older
and younger populations, respectively [3]. It is implicated in many non-communicable
conditions including cancer, autoimmune disorders, diabetes, thyroid disorders, and car-
diovascular disease [106–109], making supplementation a public health strategy [110]. Sup-
plementation can be with ergocalciferol (a form of Vitamin D2), cholecalciferol, alfacalcidol
(1α-hydroxyvitamin D), calcitriol (1,25(OH)2D) [111,112], and calcidiol (25(OH)D) [113].
Genetic variants have been identified that are associated with vitamin D deficiency
including loss of function mutations in the vitamin D receptor [114,115] in CYP2R1, which
converts cholecalciferol to calcidiol, and in Vitamin D Binding Protein (GC) that complexes
with calcidiol, chaperoning it between compartments [116].
Unfortunately, clinical studies of vitamin D status can be unclear on whether the
measurements taken are of calcidiol (25(OH)D), the inactive form, or calcitriol (1,25(OH)D),
the active form. Similarly, studies can be unclear on which metabolite is being provided in
supplementation and these factors affect our ability to explore mechanisms. However, the
majority of studies that do specify use calcidiol (25(OH)D) as a biomarker.
4. Computational Modelling of Vitamin D and Cholesterol Metabolism
Computational modelling provides a useful framework for studying the intersection
between cholesterol and vitamin D metabolism [117]. Such models are core to the systems
biology paradigm, the aim of which is to investigate biological systems in an integrated
and quantitative manner. Many different theoretical approaches can be used to model
a biological system. Stochastic modelling enables a system to be examined at a molecu-
lar level that captures Brownian dynamics or statistical uncertainty [118]. Macroscopic
modelling can employ ordinary differential equation (ODE) based [119] and spatial ODE
based [120] modelling and modal networks of interactions lend themselves to logic based
modelling [121]. Metabolic systems typically suit ODE modelling due to their high particle
number and the weak modality of their behaviour.
Elements of vitamin D metabolism have been modelled including analysis of the
pathway transition between calcidiol (25(OH)D) and calcitriol (1,25(OH)2D). In particular,
the role of vitamin D binding protein (GC) [122,123] and calcitriol (1,25(OH)2D) have
featured in a model of calcium homeostasis that promotes calcium retention [124,125].
Although not at a pathway level, the pharmacokinetics of calcidiol (25(OH)D) in HIV
patients have been modelled showing that antiretroviral drugs have no effect on vitamin
D status [126]. However, despite the clear clinical significance of vitamin D metabolism,
the pathways involved have received relatively little attention at a systems biology level
and this is reflected in the lack, at the present time, of a dedicated model of vitamin D
metabolism in the Biomodels repository [127].
More effort has been directed towards cholesterol metabolism and the cholesterol
biosynthesis pathway has been modelled at a range of levels of detail [13,41,67,128–130].
Additionally modelled are Sterol Regulatory Element Binding Protein (SREBP) mediated
feedback [131], atherosclerosis [16,132–134], and cholesterol metabolism [30,41,68,130].
The potential for new pharmaceutical therapeutic strategies that target the cholesterol
Cells 2021, 10, 2007 6 of 18
biosynthesis pathway has also been modelled [41,128]. However, at the present time, no
work has modelled the interaction between the two pathway systems.
The challenges of computationally modelling these pathway systems are related to
the paucity of parameter values that exist in the literature and online databases [128]. It
has been shown that even for the cholesterol biosynthesis pathway, which is well estab-
lished as critical to cardiovascular health and the target of clinically and commercially
important therapeutics, only approximately half the necessary parameter values have been
determined, even after pooling across relevant mammalian species [128].
5. A Bidirectional Relationship between Cholesterol and Vitamin D Metabolisms
Vitamin D deficiency is associated with an increased incidence of CVD [21,22]. Vitamin
D supplementation has been shown to improve several proxy markers of cardiovascular
health [135] including lipid profiles for calcidiol (25(OHD) [23]. Calcidiol (25(OH)D) defi-
ciency has been shown to be associated with lower HDL-C and elevated total cholesterol,
LDL-C, and triglycerides with one study reporting changes of −5.1%, +9.4%, +13.5%,
and +26.4%, respectively [23]. Vitamin D supplementation has been shown to lower total
cholesterol, LDL-C, HDL-C, and triglycerides with standardised mean differences of −0.17,
−0.12, −0.19, and −0.12, respectively, in patient cohorts [136,137]. However, paradoxically,
randomised controlled trials have consistently found no reduction in cardiovascular events
associated with vitamin D supplementation, though supplementation appears to reduce
the mortality associated with other diseases [21,24–26,112,136,138,139].
These findings are unexpected when the role of calcitriol (1,25(OH)D) is considered.
Synthesised from calcidiol (25(OHD) in the extra-renal locations of cardiomyocytes, ventric-
ular myocardium and fibroblasts [140], calcitriol (1,25(OH)D) is involved in both cardiac
remodelling and the regulation of the inflammatory processes that drive atherosclerosis
including smooth muscle cell proliferation, which stabilises plaques [141]. It has been
demonstrated experimentally that calcitriol (1,25(OH)D) hinders cholesterol uptake by
macrophages and promotes cholesterol efflux, suggesting that vitamin D metabolites may
suppress foam cell formation and therefore atherosclerosis itself [142]. In addition, it has
been demonstrated that calcitriol (1,25(OHD), but not calcidiol (25(OH)D), are inversely
correlated with coronary plaque burden in psoriasis patients [143].
The catalysis of cholesta-5,7-dien-3β-ol (7-dehydroCHOL) to cholecalciferol (VD3)
in the epidermis requires UV radiation of wavelength 280–320 nm [144], although UV
absorption can be affected by season, latitude, and lifestyle factors [145–147]. A longitudinal
study showed correlation between increasing serum calcidiol (25(OH)D) and lower serum
LDL-C in summer for healthy children across a wide latitude range [148]. The dependency
of calcidiol (25(OH)D) on adequate sun exposure has highlighted the relationship between
latitude and vitamin D deficiency [149] and between latitude and total cholesterol, LDL-C,
and coronary heart disease [150–152].
6. The Effect of Statins
Statins target the interaction catalysed by HMGCR and suppress flux through the
mevalonate and Kandutsch–Russell pathways. Statins are the primary pharmaceutical
therapy for elevated blood cholesterol, and it has been estimated that in 10,000 patients
treated for five years, they will prevent major vascular events in 1000 patients with pre-
existing CVD and 500 events in patients without [153]. However, a small proportion of
patients experience adverse effects associated with statin treatment. Amongst 10,000 pa-
tients treated for five years, statin treatment will cause ~5 cases of myopathy, 50–100 cases
of diabetes, and 5–10 strokes [153–155].
Statin induced myopathy and myalgia have been shown to be associated with vitamin
D deficiency and it has been established that these side-effects can be mitigated with
vitamin D supplementation [28,44,45,156,157].
Interestingly, vitamin D supplementation in patients receiving atorvastatin treat-
ment has been shown to lower total cholesterol and LDL-C further than atorvastatin
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alone. Supplementation has been shown to reduce total cholesterol and LDL-C by 12 and
14 mg/dL, respectively, over six weeks [29] and 26.0 and 22.6 mg/dL, respectively, over six
months [158]. Conversely, when the effect of statin treatment on vitamin D metabolism was
studied, it was initially reported that statin treatment lowers cholesterol, but raises vitamin
D, in particular calcidiol (25(OH)D) [156,159,160]. However, this result has subsequently
been rigorously refuted, and it is now understood that there is no or a negligible impact on
vitamin D [27,161].
It is also valuable to consider the effect of vitamin D metabolites on statin activity.
Calcitriol (1,25(OH)D) is known to induce the enzyme CYP3A4, which metabolises simvas-
tatin, atorvastatin, and lovastatin, and the enzyme CYP2C9, which metabolises fluvastatin
and pitavastatin [162,163]. Hence, calcitriol can influence the duration of action of statins.
Also, the effect of atorvastatin has been shown to be weaker in vitamin D deficiency [164].
7. Feedback from Vitamin D Metabolites
Negative feedback in the mevalonate and Kandutsch–Russell pathways by cholesterol
and its derivatives is well established [165–167]. However, less well known is how vitamin
D regulates these pathways. It has been shown in vivo that vitamin D deficiency leads
to reduced vitamin D receptor (VDR) activity and that this inhibits INSIG-2 expression,
which in turn releases SREBP to upregulate the mevalonate and Kandutsch–Russell path-
ways [168]. A dose response suppression has been demonstrated in vitro between calcitriol
(1,25(OH)D) and total cholesterol [168]. Furthermore, it has also been shown that the
INSIG-2 promotor contains a response element for VDR [169]. It has been observed in vivo,
that calcitriol (1,25(OH)D) and total cholesterol are inversely proportional [170], although
is worth noting that this relationship is not as strong in the plasma as in the liver [170].
A separate feedback mechanism appears to be provided by calcidiol (25(OH)D), which
has been shown to inhibit the function of HMGCR [171]. In cultured human lymphocytes,
it was shown that calcidiol (25(OH)D) inhibited HMGCR activity by 63% and 93% at
concentrations of 5 and 25 ug/mL, respectively. However, calcitriol (1,25(OH)D) only inhib-
ited HMGCR activity by 20% at both concentrations, suggesting that calcidiol (25(OH)D)
inhibition of HMGCR activity is independent of INSIG-2/SREBP regulation [171]. The
precise mechanism by which HMGCR is inhibited is unclear.
A further mode of cholesterol regulation appears with the activation of VDR, which
has been shown in vivo to increase the activity of CYP7A1, the enzyme responsible for
converting cholesterol to 7a-hydroxy cholesterol, a precursor of bile acids [170,172]. The
activity of CYP7A1 undergoes regulatory feedback to modulate bile acid metabolism. Bile
acids activate Farnesoid X Receptor (FXR), which in turn upregulates small heterodimer
partner (SHP) to suppress CYP7A1 expression and inhibit the conversion of cholesterol to
7a-hydroxy cholesterol [173]. It has been demonstrated in vivo that calcitriol (1,25(OH)D)
activation of VDR represses SHP (in a manner independent of FXR), consequently upregu-
lating CYP7A1 expression [172]. This yields a further mechanism through which calcitriol
(1,25(OHD) administration can lead to reduced serum cholesterol.
8. DHCR7 and Smith–Lemli–Opitz Syndrome
Cholesta-5,7-dien-3β-ol (7-dehydroCHOL) is the metabolite at the fork in the Kandutsch–
Russell pathway that contributes to both cholesterol and vitamin D biosynthesis. The
enzyme DHCR7 is responsible for its conversion to cholesterol. Changes to the activity of
DHCR7 can affect the balance of flux directed towards cholesterol biosynthesis and towards
vitamin D biosynthesis. Low DHCR7 activity leads to the accumulation of Cholesta-5,7-
dien-3β-ol (7-dehydroCHOL), which increases its rate of consumption on the vitamin D
pathway [174]. DHCR7 is transcriptionally regulated by SREBP as part of the feedback that
ensures homeostasis and this has been observed in statin treatment alongside proteasomal
degradation in response to cholesterol surpluses [175].
Rare genetic diseases can serve as a clinical model for elucidation of metabolic pathway
regulation. Smith–Lemli–Opitz syndrome (SLOS, OMIM #270400) is a developmental
Cells 2021, 10, 2007 8 of 18
disorder caused by mutations to the DHCR7 gene that impair its function. It affects
~1:40,000 of the population [176] and leads to an accumulation of Cholesta-5,7-dien-3β-ol
(7-dehydroCHOL) and a deficiency of cholesterol and its derivatives. Cholesta-5,7-dien-
3β-ol (7-dehydroCHOL) itself is known to reduce the activity of the enzyme HMGCR,
compounding the suppression of cholesterol synthesis [177] as well as to be a precursor of
highly reactive metabolites [178]. Impaired DHCR7 activity suggests an increase in vitamin
D biosynthesis and elevated vitamin D metabolites, and this has been observed clinically
in SLOS patients [179].
9. Variants and Mutations
Genome Wide Association Studies (GWAS) have identified DHCR7 as a locus con-
tributing to both cholesterol and vitamin D status [180,181]. As a result of its role in SLOS,
DHCR7 has been well studied and currently, the CLINVAR database [182] lists 445 variants
in DHCR7 with 168 classified as pathogenic or likely pathogenic.
The pathways leading to cholesterol and vitamin D biosynthesis are typically de-
scribed as starting with acetyl coenzyme A (AC-CoA) in the cytosol. However, acetyl
coenzyme A (AC-CoA) is itself formed in a sequence of metabolic steps employing a
tetramer of acyl-coA dehydrogenase short/branched chain (ACADSB) [183,184]. GWAS
has identified SNPs of ACADSB associated with vitamin D status and it is to be expected
that the same SNPs would affect cholesterol biosynthesis, although this has yet to be
studied [181]. CYP2R1 and CYP24A1 have also been identified as loci for SNPs affecting
vitamin D circulation [81,180,181].
10. The Molecular Pathway of Vitamin D and Cholesterol Metabolism
The pathway system that leads to the biosynthesis of vitamin D and cholesterol is
shown in Figure 2 using Systems Biology Graphical Notation (SBGN), a standardised
system of symbols for pathway maps [185]. This map is available from the Supplemen-
tary Materials in a machine readable, semantically meaningful form using the Systems
Biology Graphical Notation Markup Language format (SBGNML) [186]. It was compiled
from the Reactome pathway database [187] and spans several cellular compartments
and the extracellular space. The pathway starts in the cytosol where acetyl coenzyme A
(AC-CoA) is catalysed by the acetyl-coenzyme A acetyltransferase 2 (ACAT2) tetramer.
After a further catalysed step, the pathway enters the endoplasmic reticulum where 3-
hydroxy-3-methylglutaryl-CoA (bHMG-CoA) is transformed to mevalonic acid (MVA) in
a step catalysed by HMGCR and targeted therapeutically by statins in the treatment of
hypercholesterolaemia [41]. The pathway returns to the cytosol briefly before continuing
in the endoplasmic reticulum. Once the metabolite zymosterol is formed (ZYMOL), the
pathway branches into the Bloch pathway, which includes desmosterol as a metabolite
(DESMOL), and the Kandutsch–Russell pathway, which includes lathosterol (LTHSOL).
Both contribute to the formation of cholesterol (CHOL) in the endoplasmic reticulum, but
the Kandutsch–Russell itself also branches, with the non-cholesterol forming branch lead-
ing to vitamin D biosynthesis. The vitamin D forming branch is initiated by the transition
of cholesta-5,7-dien-3β-ol (7-dehydroCHOL) to cholecalciferol (VD3), which is catalysed
by UV radiation in the epidermis and, to a lesser extent, dermis [101]. The pathway leaves
the endoplasmic reticulum, briefly returning to form calcidiol (25(OH)D), which is sub-
sequently active in the lysosome, later transforming to calcitriol (1,25(OH)2D), the active
form, in the mitochondria. These reactions occur predominantly in the kidney, but also in
prostate, breast, and skin tissue [2,81].
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Figure 2. The cholesterol and vitamin D biosynthesis pathways as described in the Reactome database [187], along with the
three mechanisms of feedback from the vitamin D pathway that regulate the pathways. The pathways are shown using the
Systems Biology Graphical Notation [185] and this map is available for download from the Supplementary Materials in the
semantically meaningful, machine readable Systems Biology Graphical Notation Markup Language format [186].
Negative feedback occurs through regulation of the complexes of SREBP [166]. Bind-
ing of cholesterol to SREBP complexes leads to SREBP retention in the endoplasmic retic-
ulum [167]. However, at low cholesterol concentrations, SREBP complexes are freer to
undertake a series of catalysed steps that release SREBP multimers as transcription factors
capable of upregulating the enzymes responsible for catalysing some of the early steps of
the pathway [165].
Calcitriol (1,25(OH)2D) is subject to feedback regulation with an abundance lead-
ing to inhibition of CYP27B1, the enzyme that converts calcidiol (25(OH)D) to calcitriol
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(1,25(OH)2D), and stimulation of CYP24A1 (an enzyme not shown that consumes calcitriol
(1,25(OH)2D), transforming it to other metabolic forms) [2]. This feedback is mediated by
fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) (not shown) [2,81].
As shown in Figure 2, calcitriol (1,25(OH)2D) drives negative feedback in the pathway,
binding to VDR to activate the expression of INSIG, which in turn increases the retention
of SREBP in the endoplasmic reticulum [168], and de-repressing CYP7A1 expression by
inhibiting SHP, to increase cholesterol consumption [170,172]. Calcidiol (25(OH)D) is also
shown to inhibit the activity of HMGCR.
11. Discussion
Some of the observed interplay between vitamin D metabolism and cholesterol
metabolism can be explained by the feedback mechanisms and interactions described.
The three mechanisms: (i) calcitriol (1,25(OH)D) driving INSIG/SREBP mediated feed-
back [168]; (ii) calcidiol (25(OH)D) suppressing HMGCR activity [171]; and (iii) VDR
inducing CYP7A1 activity [170,172] are all consistent with the observation that vitamin D
deficiency elevates total cholesterol and LDL-C and with the observation that vitamin D
supplementation suppresses total cholesterol and LDL-C.
Similarly, observations of vitamin D status, total cholesterol, LDL-C, and latitude [150,151]
are consistent with UV exposure regulating vitamin D metabolites, which in turn use (i)
INSIG/SREBP mediated feedback; (ii) calcidiol (25(OH)D) suppression of HMGCR; and
(iii) VDR induced CYP7A1 activity to regulate the mevalonate and Kandutsch–Russell
pathways and cholesterol consumption. The observation that vitamin D supplementation
with statin treatment lowers cholesterol and its derivatives to levels below that observed in
statin treatment alone is also consistent with the action of these three mechanisms. How-
ever, because calcitriol (1,25(OH)D) also upregulates the enzymes that metabolise statins,
the effect on HMGCR may represent a balance of factors between calcidiol (25(OH)D)
suppression of HMGCR and calcitriol (1,25(OH)D) induced acceleration of statin degrada-
tion [162,163,188].
It is unclear how vitamin D supplementation mitigates the side-effects of statin
treatment, although this is largely because the side-effects themselves are poorly under-
stood [189]. It has been proposed that the side-effects of statin treatment are at least in part
triggered by deficiency of the metabolite Coenzyme Q10, which exploits HMGCR in its for-
mation [189,190]. However, this explanation goes against our current understanding, which
would predict that vitamin D supplementation reduces the activity of HMGCR, further
suppressing the formation of coenzyme Q10, and not increasing it. Calcitriol (1,25(OH)D)
induced accelerated degradation of statin would be consistent with this hypothesis as this
would make more HMGCR available. However, it would also undermine the therapeutic
value of the treatment.
It is also not clear how statin treatment succeeds in suppressing cholesterol and its
derivatives, but not the vitamin D metabolites. For vitamin D biosynthesis to remain
unaffected by statin treatment, the reduction in pathway flux along the Kandutsch–Russell
pathway would have to be restored on the vitamin D branch by shunting flux away from
the cholesterol forming branch. This could be achieved with a statin associated reduction in
the activity of DHCR7. However, there is little evidence of such a link. Instead, it has been
reported that cholesterol degrades the DHCR7 protein, suggesting that statin treatment
succeeds in propagating DHCR7, rather than suppressing it [175].
The final question is perhaps the most important. When there is strong evidence that
vitamin D supplementation improves important risk factors for CVD such as LDL-C, why
does vitamin D supplementation fail to show improvement to cardiovascular outcomes in
clinical trials? This may be linked to the observation that calcitriol (1,25(OH)D) and total
cholesterol are not as strongly inversely proportional in the plasma as in the liver [170].
Cholesterol in the plasma is a risk factor for atherosclerosis, and intriguingly, it is known
that, in addition to regulating the enzymes of the biosynthesis pathway, SREBP also regu-
lates LDLr [191]. Additionally, it has been shown that calcitriol (1,25(OH)D) treatment can
Cells 2021, 10, 2007 11 of 18
significantly upregulate ABCA1, the protein responsible for cellular cholesterol efflux [192].
Hence, it may be the case that vitamin D treatment downregulates cholesterol biosyn-
thesis, but also simultaneously upregulates cellular efflux and downregulates cellular
uptake of cholesterol. This would have the effect of enhancing the reduction in cellular
cholesterol but working against any reduction in the plasma cholesterol. However, this
is unlikely to be the whole picture. Calcitriol (1,25(OH)D) has also been shown to induce
mir-1228 [193] and it has been suggested that mir-1228 targets PCSK9 [194] as well as
LDLr (https://www.genecards.org/cgi-bin/carddisp.pl?gene=LDLR accessed on 2 July
2021). Together, this would suggest a rich interplay between vitamin D metabolism and
the factors that affect the balance between cellular and serum cholesterol.
12. Conclusions
Vitamin D metabolism and cholesterol metabolism have a complex bidirectional rela-
tionship. Certain behaviours of the two metabolisms are consistent with our understanding
of the pathways and their regulation. The evidence that increased cardiovascular risk is
associated with vitamin D deficiency and that sunlight exposure is associated with lower
cardiovascular risk are in qualitative agreement with our understanding of the feedback
and regulatory mechanisms involved. However, at present, it is not clear how vitamin D
supplementation mitigates the side-effects of statin therapy, and critically, why supplemen-
tation fails to improve cardiovascular outcomes, despite improving the biomarkers of CVD
risk. Here, we present a hypothesis that may explain the latter, with vitamin D regulating
the balance between cellular and plasma cholesterol. Filling the gaps in our understanding
of the rich interplay between these two metabolic systems has the potential to make a
dramatic contribution to our knowledge of cardiovascular health and our approaches
to therapy.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cells10082007/s1, A machine readable and biologically parsable file of Figure 1 is available in
SBGN-ML format.
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associated with severity of coronary artery atherosclerosis and incidence of acute coronary syndromes in non-diabetic cardiac
patients. Arch. Med Sci. 2019, 15, 359–368. [CrossRef] [PubMed]
110. Wilson, L.R.; Tripkovic, L.; Hart, K.H.; Lanham-New, S.A. Vitamin D deficiency as a public health issue: Using vitamin D2or
vitamin D3in future fortification strategies. Proc. Nutr. Soc. 2017, 76, 392–399. [CrossRef] [PubMed]
111. Prietl, B.; Treiber, G.; Pieber, T.R.; Amrein, K. Vitamin D and immune function. Nutrients 2013, 5, 2502–2521. [CrossRef]
112. Bjelakovic, G.; Gluud, L.L.; Nikolova, D.; Whitfield, K.; Wetterslev, J.; Simonetti, R.G.; Bjelakovic, M.; Gluud, C. Vitamin D
supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 2014, 1. [CrossRef]
113. Petkovich, M.; Bishop, C. Extended Release Calcifediol in Renal Disease, Vitamin D; Academic Press: Cambridge, MA, USA, 2018;
pp. 667–678.
114. Zmuda, J.M.; Cauley, J.; Ferrell, R.E. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol. Rev. 2000, 22,
203–217. [CrossRef]
115. Valdivielso, J.M.; Fernandez, E. Vitamin D receptor polymorphisms and diseases. Clin. Chim. Acta 2006, 371, 1–12. [CrossRef]
[PubMed]
116. Slater, N.A.; Rager, M.L.; Havrda, D.E.; Harralson, A.F. Genetic variation in CYP2R1 and GC genes associated with vitamin D
de-ficiency status. J. Pharm. Pract. 2017, 30, 31–36. [CrossRef] [PubMed]
117. McAuley, M.T.; Proctor, C.J.; Corfe, B.M.; Cuskelly, G.J.; Mooney, K.M. Nutrition research and the impact of computational
systems biology. J. Comput. Sci. Syst. Biol. 2013, 6, 271–285.
118. Wilkinson, D.J. Stochastic modelling for quantitative description of heterogeneous biological systems. Nat. Rev. Genet. 2009, 10,
122–133. [CrossRef]
Cells 2021, 10, 2007 16 of 18
119. Polynikis, A.; Hogan, S.; di Bernardo, M. Comparing different ODE modelling approaches for gene regulatory networks. J. Theor.
Biol. 2009, 261, 511–530. [CrossRef] [PubMed]
120. Klann, M.; Koeppl, H. Spatial simulations in systems biology: From molecules to cells. Int. J. Mol. Sci. 2012, 13, 7798–7827.
[CrossRef]
121. Watterson, S.; Ghazal, P. Use of logic theory in understanding regulatory pathway signaling in response to infection. Futur.
Microbiol. 2010, 5, 163–176. [CrossRef] [PubMed]
122. Dunn, J.F. Computer simulation of Vitamin D transport. Ann. N. Y. Acad. Sci. 1988, 538, 69–76. [CrossRef]
123. Chun, R.F.; Peercy, B.E.; Adams, J.; Hewison, M. Vitamin D binding protein and monocyte response to 25-Hydroxyvitamin D and
1,25-Dihydroxyvitamin D: Analysis by mathematical modeling. PLoS ONE 2012, 7, e30773. [CrossRef]
124. Peterson, M.C.; Riggs, M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.
Bone 2010, 46, 49–63. [CrossRef] [PubMed]
125. Raposo, J.F.; Sobrinho, L.G.; Ferreira, H.G. A minimal mathematical model of calcium homeostasis. J. Clin. Endocrinol. Metab.
2002, 87, 4330–4340. [CrossRef]
126. Foissac, F.; Treluyer, J.-M.; Souberbielle, J.-C.; Rostane, H.; Urien, S.; Viard, J.-P. Vitamin D3 supplementation scheme in HIV-
infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol. Br. J. Clin. Pharmacol. 2013, 75, 1312–1320.
[CrossRef] [PubMed]
127. Chelliah, V.; Juty, N.; Ajmera, I.; Ali, R.; Dumousseau, M.; Glont, , M.; Hucka, M.; Jalowicki, G.; Keating, S.; Knight-Schrijver, V.;
et al. BioModels: Ten-year anniversary. Nucleic Acids Res. 2014, 43, D542–D548. [CrossRef]
128. Benson, H.E.; Watterson, S.; Sharman, J.L.; Mpamhanga, C.P.; Parton, A.; Southan, C.; Harmar, A.J.; Ghazal, P. Is systems
pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway. Br. J. Pharma. 2017,
174, 4362–4382. [CrossRef] [PubMed]
129. Pool, F.; Currie, R.; Sweby, P.K.; Salazar, J.D.; Tindall, M.J. A mathematical model of the mevalonate cholesterol biosynthesis
pathway. J. Theor. Biol. 2018, 443, 157–176. [CrossRef]
130. Pool, F.; Sweby, P.K.; Tindall, M.J. An integrated mathematical model of cellular cholesterol biosynthesis and lipoprotein
metabolism. Processes 2018, 6, 134. [CrossRef]
131. Bhattacharya, B.S.; Sweby, P.K.; Minihane, A.-M.; Jackson, K.; Tindall, M.J. A mathematical model of the sterol regulatory element
binding protein 2 cholesterol biosynthesis pathway. J. Theor. Biol. 2014, 349, 150–162. [CrossRef] [PubMed]
132. El Khatib, N.; Génieys, S.; Kazmierczak, B.; Volpert, V. Mathematical modelling of atherosclerosis as an inflammatory disease.
Philos. Trans. R. Soc. Math. Phys. Eng. Sci. 2009, 367, 4877–4886. [CrossRef]
133. Bulelzai, M.; Dubbeldam, J.L. Long time evolution of atherosclerotic plaques. J. Theor. Biol. 2012, 297, 1–10. [CrossRef] [PubMed]
134. Friedman, A.; Hao, W. A Mathematical model of atherosclerosis with reverse cholesterol transport and associated risk factors.
Bull. Math. Biol. 2014, 77, 758–781. [CrossRef]
135. Rai, V.; Agrawal, D.K. Role of vitamin D in cardiovascular diseases. Endocrinol. Metab. Clin. N. Am. 2017, 46, 1039–1059.
[CrossRef]
136. Skaaby, T.; Husemoen, L.L.; Pisinger, C.; Jørgensen, T.; Thuesen, B.H.; Fenger, M.; Linneberg, A. Vitamin D status and changes in
car-diovascular risk factors: A prospective study of a general population. Cardiology 2012, 123, 62–70. [CrossRef] [PubMed]
137. Dibaba, D.T. Effect of vitamin D supplementation on serum lipid profiles: A systematic review and meta-analysis. Nutr. Rev.
2019, 77, 890–902. [CrossRef] [PubMed]
138. Skaaby, T.; Husemoen, L.L.; Pisinger, C.; Jørgensen, T.; Thuesen, B.H.; Fenger, M.; Linneberg, A. Vitamin D status and incident
cardi-ovascular disease and all-cause mortality: A general population study. Endocrine 2013, 43, 618–625. [CrossRef] [PubMed]
139. Jorde, R.; Figenschau, Y.; Emaus, N.; Hutchinson, M.; Grimnes, G. Serum 25-Hydroxyvitamin D levels are strongly related to
systolic blood pressure but do not predict future hypertension. Hypertension 2010, 55, 792–798. [CrossRef] [PubMed]
140. Chen, S.; Glenn, D.J.; Ni, W.; Grigsby, C.; Olsen, K.; Nishimoto, M.; Law, C.S.; Gardner, D.G. Expression of the Vitamin D receptor
is increased in the hypertrophic heart. Hypertension 2008, 52, 1106–1112. [CrossRef]
141. Norman, P.; Powell, J. Vitamin D and cardiovascular disease. Circ. Res. 2014, 114, 379–393. [CrossRef]
142. Riek, A.E.; Oh, J.; Bernal-Mizrachi, C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol
metabolism in type 2 diabetic patients. J. Steroid Biochem. Mol. Biol. 2013, 136, 309–312. [CrossRef]
143. Playford, M.P.; Dey, A.K.; Zierold, C.; Joshi, A.A.; Blocki, F.; Bonelli, F.; Rodante, J.A.; Harrington, C.L.; Rivers, J.P.; Elnabawi,
Y.A.; et al. Serum active 1,25 (OH) 2D, but not inactive 25 (OH) D vitamin D levels are associated with cardiometabolic and
cardio-vascular disease risk in psoriasis. Atherosclerosis 2019, 289, 44–50. [CrossRef]
144. Mohania, D.; Chandel, S.; Kumar, P.; Verma, V.; Digvijay, K.; Tripathi, D.; Choudhury, K.; Mitten, S.K.; Shah, D. Ultraviolet
radiations: Skin defense-damage mechanism. Ultrav. Light Hum. Health Dis. Environ. 2017, 996, 71–87. [CrossRef]
145. Maxwell, J.D. Seasonal variation in vitamin D. Proc. Nutr. Soc. 1994, 53, 533–543. [CrossRef] [PubMed]
146. Wacker, M.; Holick, M.F. Sunlight and vitamin D: A global perspective for health. Dermatoendocrinology 2013, 5, 51–108. [CrossRef]
[PubMed]
147. Pereira, L.A.; Luz, F.B.; Carneiro, C.M.M.D.O.; Xavier, A.L.R.; Kanaan, S.; Miot, H.A. Evaluation of vitamin D plasma levels after
mild exposure to the sun with photoprotection. An. Bras. Dermatol. 2019, 94, 56–61. [CrossRef]
Cells 2021, 10, 2007 17 of 18
148. Nikooyeh, B.; Abdollahi, Z.; Hajifaraji., M.; Alavi-Majd, H.; Salehi, F.; Yarparvar, A.H.; Neyestani, T.R. Healthy changes in some
cardiometabolic risk factors accompany the higher summertime serum 25-hydroxyvitamin D concentrations in Iranian children:
National Food and Nutrition Surveillance. Public Health Nutr. 2018, 21, 2013–2021. [CrossRef]
149. Huotari, A.; Herzig, K.-H. International Journal of Circumpolar Health Vitamin D and living in northern latitudes, an endemic
risk area for vitamin D deficiency. Circumpolar Health 2008, 67, 164–178. [CrossRef]
150. Grimes, D.S.; Hindle, E.; Dyer, T. Sunlight, cholesterol and coronary heart disease. QJM Int. J. Med. 1996, 89, 579–590. [CrossRef]
151. Liu, Y.; Brook, R.D.; Liu, X.; Byrd, J.B. Abstract P300: Countries’ geographic latitude and their populations’ cholesterol and blood
pressure. Hypertension 2018, 72, 300. [CrossRef]
152. Scragg, R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int. J.
Epidemiol. 1981, 10, 337–341. [CrossRef] [PubMed]
153. Collins, R.; Reith, C.; Emberson, J.; Armitage, J.; Baigent, C.; Blackwell, L.; Blumenthal, R.; Danesh, J.; Smith, G.D.; DeMets, D.;
et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016, 388, 2532–2561. [CrossRef]
154. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: A randomised placebocontrolled trial. Lancet 2002, 360, 7–22. [CrossRef]
155. Pinal-Fernandez, I.; Casal-Dominguez, M.; Mammen, A.L. Statins: Pros and cons. Med. Clínica 2018, 150, 398–402. [CrossRef]
156. Gupta, A.; Thompson, P.D. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011, 215, 23–29. [CrossRef]
[PubMed]
157. Turner, R.M.; Pirmohamed, M. Statin-related myotoxicity: A comprehensive review of pharmacokinetic, pharmacogenomic and
muscle components. J. Clin. Med. 2019, 9, 22. [CrossRef]
158. Qin, X.F.; Zhao, L.S.; Chen, W.R.; Wang, H. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercho-
lesterolemia: A randomized placebo-controlled trial. Clin. Nutr. 2015, 34, 201–206. [CrossRef]
159. Aloia, J.F.; Li-Ng, M.; Pollack, S. Statins and vitamin D. Am. J. Cardiol. 2007, 8, 1329. [CrossRef] [PubMed]
160. Pérez-Castrillón, J.L.; Vega, G.; Abad, L.; Sanz, A.; Chaves, J.; Hernandez, G.; Dueñas, A. Effects of atorvastatin on Vitamin D
levels in patients with acute ischemic heart disease. Am. J. Cardiol. 2007, 99, 903–905. [CrossRef] [PubMed]
161. Sahebkar, A.; Reiner, Ž.; Simental-Mendía, L.; Ferretti, G.; Della Corte, C.; Nobili, V. Impact of statin therapy on plasma vitamin D
levels: A systematic review and meta-analysis. Curr. Pharm. Des. 2017, 23, 861–869. [CrossRef]
162. Thummel, K.E.; Brimer, C.; Yasuda, K.; Thottassery, J.; Senn, T.; Lin, Y.; Ishizuka, H.; Kharasch, E.; Schuetz, J.; Schuetz, E.
Transcriptional control of intestinal cytochrome P-4503A by 1α, 25-dihydroxy vitamin D3. Mol. Pharmacol. 2001, 60, 1399–1406.
[CrossRef]
163. Drocourt, L.; Ourlin, J.-C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.-J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by
the Vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 2002, 277, 25125–25132. [CrossRef]
164. Pérez-Castrillón, J.L.; Manteca, L.A.; Vega, G.; Montes, J.D.P.; De Luis, D.; Laita, A.D. Vitamin D levels and lipid response to
atorvastatin. Int. J. Endocrinol. 2009, 2010, 320721. [CrossRef]
165. Brown, M.S.; Goldstein, J.L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound
transcription factor. Cell 1997, 89, 331–340. [CrossRef]
166. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in
the liver. J. Clin. Investig. 2002, 109, 1125–1131. [CrossRef]
167. Bengoechea-Alonso, M.T.; Ericsson, J. SREBP in signal transduction: Cholesterol metabolism and beyond. Curr. Opin. Cell Biol.
2007, 19, 215–222. [CrossRef] [PubMed]
168. Li, S.; He, Y.; Lin, S.; Hao, L.; Ye, Y.; Lv, L.; Sun, Z.; Fan, H.; Shi, Z.; Li, J.; et al. Increase of circulating cholesterol in vitamin
D deficiency is linked to reduced vitamin D receptor activity via the Insig-2/SREBP-2 pathway. Mol. Nutr. Food Res. 2015, 60,
798–809. [CrossRef]
169. Lee, S.; Lee, D.-K.; Choi, E.; Lee, J.W. Identification of a functional vitamin D response element in the murine insig-2 promoter
and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol. Endocrinol. 2005, 19, 399–408. [CrossRef]
170. Quach, H.P.; Dzekic, T.; Bukuroshi, P.; Pang, K.S. Potencies of vitamin D analogs, 1α-hydroxyvitamin D3, 1α-hydroxyvitamin
D2 and 25-hydroxyvitamin D3, in lowering cholesterol in hypercholesterolemic mice in vivo. Biopharm. Drug Dispos. 2018, 39,
196–204. [CrossRef]
171. Defay, R.; Astruc, M.E.; Roussillon, S.; Descomps, B.; de Paulet, A.C. DNA synthesis and 3-hydroxy-3-methylglutaryl CoA
reductase activity in PHA stimulated human lymphocytes: A comparative study of the inhibitory effects of some oxysterols with
special reference to side chain hydroxylated derivatives. Biochem. Biophys. Res. Commun. 1982, 106, 362–372. [CrossRef]
172. Chow, E.C.; Magomedova, L.; Quach, H.P.; Patel, R.; Durk, M.R.; Fan, J.; Maeng, H.-J.; Irondi, K.; Anakk, S.; Moore, D.D.;
et al. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
Gastroenterology 2014, 146, 1048.e7–1059.e7. [CrossRef]
173. Chambers, K.F.; Day, P.E.; Aboufarrag, H.T.; Kroon, P.A. Polyphenol effects on cholesterol metabolism via bile acid biosynthesis,
CYP7A1: A Review. Nutrients 2019, 11, 2588. [CrossRef]
174. Prabhu, A.; Luu, W.; Li, D.; Sharpe, L.; Brown, A.J. DHCR7: A vital enzyme switch between cholesterol and vitamin D production.
Prog. Lipid Res. 2016, 64, 138–151. [CrossRef]
175. Prabhu, A.; Luu, W.; Sharpe, L.; Brown, A.J. Cholesterol-mediated degradation of 7-Dehydrocholesterol reductase switches the
balance from cholesterol to vitamin D synthesis. J. Biol. Chem. 2016, 291, 8363–8373. [CrossRef]
Cells 2021, 10, 2007 18 of 18
176. Cross, J.L.; Iben, J.; Simpson, C.L.; Thurm, A.; Swedo, S.; Tierney, E.; Bailey-Wilson, J.E.; Biesecker, L.G.; Porter, F.D.; Wassif, C.A.
Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets.
Clin. Genet. 2015, 87, 570–575. [CrossRef]
177. Honda, M.; Tint, G.S.; Honda, A.; Nguyen, L.B.; Chen, T.S.; Shefer, S. 7-Dehydrocholesterol down-regulates cholesterol biosynthe-
sis in cultured Smith-Lemli-Opitz syndrome skin fibroblasts. J. Lipid Res. 1998, 39, 647–657. [CrossRef]
178. Lamberson, C.R.; Muchalski, H.; McDuffee, K.B.; Tallman, K.A.; Xu, L.; Porter, N.A. Propagation rate constants for the peroxidation
of sterols on the biosynthetic pathway to cholesterol. Chem. Phys. Lipids 2017, 207, 51–58. [CrossRef] [PubMed]
179. Movassaghi, M.; Bianconi, S.; Feinn, R.; Wassif, C.A.; Porter, F.D. Vitamin D levels in Smith-Lemli-Opitz syndrome. Am. J. Med.
Genet. 2017, 173, 2577–2583. [CrossRef] [PubMed]
180. Wang, T.J.; Zhang, F.; Richards, J.B.; Kestenbaum, B.; Van Meurs, J.B.; Berry, D.; Kiel, D.P.; Streeten, E.A.; Ohlsson, C.; Koller, D.L.;
et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010, 376, 180–188.
[CrossRef]
181. Ahn, J.; Yu, K.; Stolzenberg-Solomon, R.; Simon, K.C.; McCullough, M.L.; Gallicchio, L.; Jacobs, E.J.; Ascherio, A.; Helzlsouer, K.;
Jacobs, K.; et al. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 2010, 19, 2739–2745. [CrossRef]
[PubMed]
182. Landrum, M.J.; Chitipiralla, S.; Brown, G.R.; Chen, C.; Gu, B.; Hart, J.; Hoffman, D.; Jang, W.; Kaur, K.; Liu, C.; et al. ClinVar:
Improvements to accessing data. Nucleic Acids Res. 2020, 48, D835–D844. [CrossRef] [PubMed]
183. Andresen, B.S.; Christensen, E.; Corydon, T.J.; Bross, P.; Pilgaard, B.; Wanders, R.J.; Ruiter, J.P.; Simonsen, H.; Winter, V.; Knudsen,
I.; et al. Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: Identification
of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in iso-leucine and
valine metabolism. Am. J. Hum. Genet. 2000, 67, 1095–1103. [PubMed]
184. Gibson, K.M.; Burlingame, T.G.; Hogema, B.; Jakobs, C.; Schutgens, R.B.H.; Millington, D.; Roe, C.R.; Roe, D.S.; Sweetman,
L.; Steiner, R.; et al. 2-Methylbutyryl-coenzyme a dehydrogenase deficiency: A new inborn error of L-isoleucine metabolism.
Pediatric Res. 2000, 47, 830–833. [CrossRef]
185. Le Novere, N.; Hucka, M.; Mi, H.; Moodie, S.; Schreiber, F.; Sorokin, A.; Demir, E.; Wegner, K.; Aladjem, M.I.; Wimalaratne, S.M.;
et al. The systems biology graphical notation. Nat. Biotech. 2009, 27, 735–741. [CrossRef]
186. Van Iersel, M.P.; Villéger, A.C.; Czauderna, T.; Boyd, S.E.; Bergmann, F.T.; Luna, A.; Demir, E.; Sorokin, A.; Dogrusoz, U.;
Matsuoka, Y.; et al. Software support for SBGN maps: SBGN-ML and LibSBGN. Bioinformatics 2012, 28, 2016–2021. [CrossRef]
187. Fabregat, A.; Sidiropoulos, K.; Viteri, G.; Marin-Garcia, P.; Ping, P.; Stein, L.; D’Eustachio, P.; Hermjakob, H. Reactome diagram
viewer: Data structures and strategies to boost performance. Bioinformatics 2017, 34, 1208–1214. [CrossRef] [PubMed]
188. Bhattacharyya, S.; Maitra, A. Possible mechanisms of interaction between statins and vitamin D. Qjm. Int. J. Med. 2012, 105,
487–491. [CrossRef] [PubMed]
189. Nikolic, D.; Banach, M.; Chianetta, R.; Luzzu, L.M.; Stoian, A.P.; Diaconu, C.C.; Citarrella, R.; Montalto, G.; Rizzo, M. An overview
of statin-induced myopathy and perspectives for the future. Expert Opin. Drug Saf. 2020, 19, 601–615. [CrossRef] [PubMed]
190. Banach, M.; Serban, C.; Ursoniu, S.; Rysz, J.; Muntner, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.; Watts, G.; et al. Statin therapy
and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res.
2015, 99, 329–336. [CrossRef] [PubMed]
191. Goldstein, J.L.; DeBose-Boyd, R.A.; Brown, M.S. Protein sensors for membrane sterols. Cell 2006, 124, 35–46. [CrossRef]
192. Munir, M.T.; Ponce, C.; Santos, J.M.; Sufian, H.B.; Al-Harrasi, A.; Gollahon, L.S.; Hussain, F.; Rahman, S.M. VD3 and LXR
agonist (T0901317) combination demonstrated greater potency in inhibiting cholesterol accumulation and inducing apoptosis via
ABCA1-CHOP-BCL-2 cascade in MCF-7 breast cancer cells. Mol. Biol. Rep. 2020, 47, 7771–7782. [CrossRef]
193. Lisse, T.S.; Chun, R.F.; Rieger, S.; Adams, J.S.; Hewison, M. Vitamin D activation of functionally distinct regulatory miRNAs in
primary human osteoblasts. J. Bone Miner. Res. 2013, 28, 1478–1488. [CrossRef]
194. Decourt, C.; Janin, A.; Moindrot, M.; Chatron, N.; Nony, S.; Muntaner, M.; Dumont, S.; Divry, E.; Dauchet, L.; Meirhaeghe, A.;
et al. PCSK9 post-transcriptional regulation: Role of a 3’ UTR microRNA-binding site variant in linkage disequilibrium with c.
1420G. Atherosclerosis 2020, 314, 63–70. [CrossRef] [PubMed]
